RxDoctor Payments Data

Kersthine Andre, MD

Endocrinology, Diabetes & Metabolism · Monroeville, PANPI 1710326293

Payments from drug & device makers

$3,419in general payments, 2019–2025

Across 70 payments — averaging $48.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$995
  • Abbott$491
  • Cequr Corporation$476
  • Sanofi-aventis U.S. LLC$441
  • Novo Nordisk$427
  • Dexcom, Inc.$161
  • plus $428 from 11 others

What the payments were for

  • Food & beverage$3,02488%
  • Education$39512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,419 in reported general payments places this provider in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,999
Medicare patients
229
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide191$311,095
TrulicityDulaglutide130$183,209
Teriparatide30$156,409
JardianceEmpagliflozin118$145,919
MounjaroTirzepatide61$75,268
Tresiba Flextouch U-100Insulin Degludec51$46,210
Tresiba Flextouch U-200Insulin Degludec43$42,619
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$40,637
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog60$39,197
Humulin R U-500 KwikpenInsulin Regular, Human29$39,125
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$32,143
Lantus SolostarInsulin Glargine,hum.Rec.Anlog208$30,543
Novolog FlexpenInsulin Aspart63$25,392
Humalog Kwikpen U-100Insulin Lispro51$22,332
Nano 2nd Gen Pen NeedlePen Needle, Diabetic148$19,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$427$318,667209 claims
Lilly USA, LLCTrulicity, Mounjaro$35$258,477191 claims
Sanofi-aventis U.S. LLCLantus$441$2,96611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

Other endocrinology, diabetes & metabolism in Monroeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →